From the #StemCellEvidence Alert: Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial by Russo et al.

New from #StemCellEvidence: Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma by Sidana et al. stemcellevidence.com/alerts/article…

The #Transfusion Evidence Round-Up: Best of the TEL 2024 is out! See all the top articles here: transfusionevidencelibrary.com/alerts/latest Each one has an easy-to-read PICO summary.

From the #StemCellEvidence Alert: Soluble MICA concentrations and genetic variability of MICA and its NKG2D receptor as factors affecting Graft-versus-Host Disease development after allogeneic haematopoietic stem cell transplantation by Siemaszko et al. stemcellevidence.com/alerts/article…

New from #StemCellEvidence: Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes by Spellman et al. stemcellevidence.com/alerts/article…

🚨PLEASE SHARE – Urgent search for donors 🚨 Natassa, aged 19, urgently needs a stem cell donor. In April she was diagnosed with chronic myeloid leukaemia, but two weeks ago this turned into acute lymphoblastic leukaemia. #NatassasMissionToRemission

From the #Transfusion Evidence Round-Up: Best of the TEL 2024: Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage by Connolly et al. transfusionevidencelibrary.com/alerts/article…

From the #Transfusion Evidence Round-Up: Best of the TEL 2024: Prehospital #tranexamicacid is associated with a survival benefit without an increase in complications: Results of two harmonized randomized clinical trials by Mazzei et al. transfusionevidencelibrary.com/alerts/article…

New from the #Transfusion Evidence Round-Up: Best of the TEL 2024: Two-year outcomes following a randomised platelet transfusion trial in preterm infants by Moore et al. transfusionevidencelibrary.com/alerts/article…

New from #StemCellEvidence: Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation by Abboud et al. stemcellevidence.com/alerts/article…

From the #StemCellEvidence Alert: Quantifying HLA Mismatches at Epitope Level in Haplo-HSCT: Impact in the Outcome in Strategies Using PTCy by Gil-Etayo et al. stemcellevidence.com/alerts/article…

New from #StemCellEvidence: Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia by Gui et al. stemcellevidence.com/alerts/article…

From the #StemCellEvidence Alert: Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease by Mahmoudjafari et al. stemcellevidence.com/alerts/article…

New from #StemCellEvidence: Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis by Meyer et al. stemcellevidence.com/alerts/article…

An exciting new post is available that offers the opportunity to become a Locum Consultant Haematologist with an interest in Advanced Cellular Therapeutics. You will be a key member of both NHS Blood and Transplant (NHSBT) and Bedfordshire Hospitals NHS Foundation Trust teams.

From the #StemCellEvidence Alert: Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation (...) by Ortí et al. stemcellevidence.com/alerts/article…

🌟Big shout out to our colleagues over in CMT - this is incredible - what a start to the year! 🌟#nhsbtproud

New from #StemCellEvidence: Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors (...) Passweg et al. stemcellevidence.com/alerts/article…

From the #StemCellEvidence Alert: Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation by Pasvolsky et al. stemcellevidence.com/alerts/article…